Authorities in China have approved a drug for the treatment of Alzheimers disease, the first nepany that will be bringing the new drug to market.这一机制在上海的绿谷制药公司进行的临床试验中得到了证实，该公司将把这种新药推向市场。Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimers in as little as four weeks, according to a statement from Green Valley.绿谷制药公司发布的声明中说，对818位病人进行的临床试验发现从统计数据来看，用褐藻提取物制成的甘露特钠胶囊在短短四周内就能改善老年痴呆人群的认知功能。These results advance our understanding of the mechanisms that play a role in Alzheimers disease and imply that the gut microbiome is a valid target for the development of therapies, neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.神经学家Philip Scheltens是绿谷制药公司顾问，也是阿姆斯特丹阿尔茨海默症中心负责人，他在声明中说：“这些结果促进了我们对阿尔茨海默症发病机制的理解，并暗示肠道微生物群是治疗发展的有效靶点。”